Trial Profile
A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Cetuximab; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 09 Jun 2022 Status changed from active, no longer recruiting to completed.
- 27 Oct 2020 Planned End Date changed from 1 Jul 2023 to 6 Jul 2022.
- 27 Oct 2020 Planned primary completion date changed from 1 Aug 2019 to 20 Nov 2020.